What is a Japanese quasi-drug? A guide for overseas buyers

Under Japan's Pharmaceutical and Medical Device Act (薬機法, yakki-hō), personal care and pharmaceutical products are classified into three primary tiers: cosmetics (化粧品), quasi-drugs (医薬部外品), and pharmaceuticals (医薬品). Quasi-drugs sit in the middle. They are regulated more strictly than cosmetics, but they do not require a prescription or the clinical trials expected of drugs.

The distinction matters because it governs what a product is legally allowed to claim on its packaging. A cosmetic can describe what it does cosmetically — "moisturizes," "softens" — but cannot claim to treat or prevent a condition. A quasi-drug is permitted to claim a defined set of mild-therapeutic benefits because its active ingredients have been reviewed and approved by the Ministry of Health, Labour and Welfare (MHLW).

Quasi-drug status permits a narrow but commercially important set of functional claims. The most common categories seen on Japanese drugstore shelves include:

• Medicated whitening (薬用美白) — prevention of spots and freckles caused by sun exposure
• Anti-wrinkle (シワ改善) — recently expanded to allow "improvement" rather than just prevention
• Acne prevention (ニキビを防ぐ) — typically via ingredients like isopropyl methylphenol or salicylic acid
• Anti-dandruff and scalp care (ふけ・かゆみを防ぐ)
• Antiperspirant and deodorant (制汗・デオドラント)
• Medicated toothpaste (薬用歯磨き) — cavity prevention, gum care
• Hair regrowth and fall prevention (育毛・脱毛予防)

Japanese packaging is consistent: the words 医薬部外品 will appear on the primary display panel, usually near the brand name or in a box near the ingredient list. You will often see a corresponding English phrase such as "Quasi-drug" or occasionally "Medicinal," though neither is required for domestic sale.

The ingredient list is also structured differently. Quasi-drugs are required to list the approved active ingredient (有効成分) separately from the other ingredients (その他の成分). This is the fastest way for a buyer to confirm quasi-drug status from a product image: if you see that two-part ingredient structure, you are looking at a quasi-drug.

Several of Japan's largest skincare categories are effectively quasi-drug categories: medicated whitening serums, medicated acne lines, medicated sunscreens, and medicated scalp care. Major brands often launch a flagship quasi-drug SKU as the centerpiece of a line, with supporting regular cosmetics around it.

For Japanese consumers, the quasi-drug designation signals a higher level of efficacy testing and ingredient approval. That signal translates directly into price premium and shelf prominence at drugstores. The shelf logic favors quasi-drugs: they are often placed at eye level, featured in POP material, and nominated for @cosme Best Cosme awards in their own categories.

A quasi-drug in Japan is not automatically compliant anywhere else. When you import a Japanese quasi-drug into the US, EU, ASEAN markets, or elsewhere, you will need to re-evaluate the active ingredient list against destination regulations. An active ingredient approved under MHLW's quasi-drug framework may be a regulated drug ingredient in another country, a cosmetic ingredient, or occasionally not permitted at all.

That said, quasi-drug status in Japan is a useful proxy for product quality when sourcing. Manufacturers producing quasi-drugs must maintain GMP-compliant facilities, undergo MHLW inspections, and document stability and safety testing beyond what regular cosmetics require. The same facility, the same formulation discipline, and the same QA systems often produce both quasi-drug and cosmetic lines for the same brand.